Menu
  • Join
  • Login
  • Contact
 

New medicines special interest group

Drugs developed from small molecules are increasingly playing an important role in therapeutics, with many becoming newly approved drugs (42 newly approved as New Molecular Entities vs 17 Biologics License Applications in 2018). Conventional structure-activity relationship studies as well as drug design using artificial intelligence are being developed in order to discover drug candidates.

Thousands of compounds have been isolated from natural products, developed into pharmaceuticals and are used in medicinal chemistry research with the aim of providing new molecular structure entities. Evidence-based approaches in the scientific study of herbal medicines will aid in the proper development and use of natural products.
Biotechnology-based pharmaceutical products have been the focus of drugs recently approved by the US Food and Drug Administration for various treatments. Research efforts focused on pharmaceutical biotechnology have recently intensified, including in bioanalytical methods, biomarkers, biosimilars, protein interactions, cell therapies (e.g. stem cell transplantation), gene therapies (e.g. CRISPR technology) and vaccines.

Interdisciplinary research efforts are highly crucial in the promotion of team science by bridging silos in the scientific community and addressing multifactorial problems in research. This supports the importance of linking these research areas described above to the area of pharmacology so that we can understand how these newly developed medicines act in the body.

The Special Interest Group on New Medicines will provide a platform for the discussion of a wide range of research topics in the pharmaceutical sciences related to drug discovery and development. Importantly, this includes early stage drug development, with research areas in medicinal chemistry, natural medicines, pharmacology, cell and gene therapies and biologics. Synergy of these topics will corroborate the important role of pharmacists in health care, with new insights in emerging trends in drug discovery and development.

 

How we work

The special interest group is chaired by Prof. Takuya Kumamoto (Hiroshima University, Japan).


Contact

For more information about this group or to get involved, email NewMeds@fip.org

Last update 12 November 2019

FIP Congresses